Key Considerations: Who Cannot Take Ozempic?

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic and other GLP-1 receptor agonists represent a major advancement in weight management, but they are not suitable for all patients. Approximately 15–20% of individuals seeking weight loss medication have absolute or relative contraindications that make GLP-1 therapy unsafe. Knowing who cannot take these medications is just as important as understanding who benefits most from them.

Absolute Medical Contraindications to GLP-1 Medications

Certain medical conditions completely prohibit the use of Ozempic, semaglutide, or tirzepatide. Patients with a personal history of medullary thyroid carcinoma (MTC) must avoid all GLP-1 receptor agonists, because these drugs stimulate calcitonin release and have been linked to C-cell tumors in animal studies. Additionally, individuals with multiple endocrine neoplasia syndrome type 2 (MEN2), a rare genetic condition that increases thyroid cancer risk, should not use GLP-1 medications under any circumstances.

Severe pancreatitis history or pancreatic disease represents another absolute barrier. GLP-1 agonists slow gastric emptying, which can theoretically increase pancreatitis risk in susceptible patients. Patients who have experienced acute pancreatitis without a clear, reversible cause must consult an endocrinologist before any GLP-1 therapy. Uncontrolled diabetic ketoacidosis (DKA) or type 1 diabetes mellitus in certain contexts also contraindicates these medications, though type 2 diabetes patients with stable glucose control generally tolerate GLP-1s well.

Relative Contraindications and Risk Factors for Caution

Relative contraindications do not automatically exclude patients but require careful medical evaluation and informed consent. Individuals with a family history of medullary thyroid cancer or MEN2 should discuss genetic testing and baseline thyroid function before starting semaglutide or tirzepatide, even if they do not carry the mutation themselves. Patients with a personal or family history of diabetic retinopathy—especially those with preexisting vision changes—need ophthalmologic clearance, because rapid weight loss and improved glycemic control can sometimes worsen retinopathy temporarily in susceptible individuals.

Pregnancy and breastfeeding are contraindications to GLP-1 therapy. These medications cross the placenta and are secreted in breast milk, with insufficient safety data in pregnant or nursing populations. Women of childbearing age must use reliable contraception during treatment and discuss family planning goals with their provider. Patients taking other medications that slow intestinal transit, such as opioid analgesics, may experience compounded gastrointestinal effects and require dose adjustment or alternative therapies.

Gallbladder and Gastrointestinal Complications That Warrant Caution

Rapid weight loss from any therapy—including GLP-1 medications—increases the risk of gallstone formation and cholecystitis. Patients with a history of gallstones or cholecystectomy (gallbladder removal) should be monitored closely if GLP-1 therapy is initiated, because the medications accelerate weight loss and may trigger new stone formation. Those with inflammatory bowel disease (IBD), including Crohn's disease or ulcerative colitis, face increased gastrointestinal side effect risk. While GLP-1 medications do not directly worsen IBD, the nausea, vomiting, and altered gut motility they cause can complicate disease management.

Patients with severe gastroparesis (delayed stomach emptying) or a history of gastric bypass surgery should avoid GLP-1 agonists altogether. These medications further slow gastric emptying and can cause severe nausea, vomiting, and abdominal pain in these populations. Individuals with acute cholecystitis, pancreatitis, or other active gastrointestinal emergencies must postpone GLP-1 initiation until the acute condition resolves and baseline function stabilizes.

Personalized Assessment: Why Genetic Testing Matters When Screening Contraindications

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

For patients with relative contraindications—such as borderline pancreatic function or family history of thyroid cancer—genetic insights can help determine whether a different peptide compound, lower starting dose, or alternative weight loss approach is safer. PlexusDx compounded semaglutide injection ($189/mo) and tirzepatide options allow precise dose titration for patients who would benefit from GLP-1 therapy but need cautious introduction. The Precision Peptide Genetic Test ($298) maps 14 metabolic pathways and 49 peptides, offering a data-driven foundation for contraindication assessment alongside clinical judgment.

When GLP-1 Alternatives May Be Safer or More Effective

For patients who cannot safely take Ozempic or other GLP-1 agonists, alternative weight management strategies exist. Phentermine and phendimetrazine are sympathomimetic amines that work through a different mechanism (norepinephrine release) and may be suitable for some patients with contraindications to GLP-1s. Other options include naltrexone/bupropion combination therapy, which targets hypothalamic appetite centers, or behavioral interventions combined with structured nutrition support. A licensed provider must conduct a detailed risk–benefit analysis to identify the safest path forward.

PlexusDx offers the Microdose GLP-1 Protocol ($129/mo) as an entry point for patients who are cautious about full-dose GLP-1 therapy or who show signs of sensitivity. This lower-dose approach allows providers to assess tolerance and efficacy before escalating to standard formulations. Patients with complicated medical histories benefit from a precision health evaluation that integrates genetic testing, lifestyle factors, and comorbidities to design a personalized weight loss plan that avoids contraindicated medications and maximizes safety and results.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can I take semaglutide if I have a family history of thyroid cancer?

Family history of medullary thyroid cancer (MTC) or MEN2 syndrome requires careful evaluation before starting semaglutide. Discuss baseline thyroid screening and consider genetic counseling. PlexusDx providers can help assess individual risk and determine whether your family history creates an absolute contraindication or justifies closer monitoring during treatment.

What happens if I have gallstones or a history of pancreatitis?

Patients with a history of gallstones are at higher risk of cholecystitis during rapid weight loss, and those with unexplained pancreatitis must avoid GLP-1 medications entirely. If you have a clear, reversible cause of past pancreatitis (such as gallstones since removed), a gastroenterologist or endocrinologist may clear you for GLP-1 therapy with close monitoring.

Is Ozempic safe if I am planning to become pregnant?

No. GLP-1 medications including semaglutide are contraindicated during pregnancy and breastfeeding. If you are planning pregnancy, discuss timing with your provider and switch to a safe alternative therapy. PlexusDx can help you plan a weight management strategy that aligns with your reproductive goals.

Can the Precision Peptide Genetic Test identify hidden contraindications?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What if I have inflammatory bowel disease—can I still use semaglutide?

Patients with IBD (Crohn's disease or ulcerative colitis) face higher gastrointestinal side effect risks on GLP-1 medications. While not an absolute contraindication, IBD requires careful monitoring, dose adjustment, and coordination with your gastroenterologist. PlexusDx compounded semaglutide allows flexible dosing and the Microdose GLP-1 Protocol ($129/mo) may be a safer starting point for IBD patients.

Related Reading

• Lifemd Ozempic
• Eden Ozempic
• Ro Ozempic
• Mochi Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.